Description
loading
-
-
-
Implementation


Scroll down for more
Centered Image Centered Image Centered Image Centered Image Centered Image Centered Image Centered Image Centered Image Centered Image

1. Cardiovascular Disease Issues

While China has made initial progress in the prevention and control of cardiovascular diseases, it faces new and severe challenges. Overall, the incidence and mortality rates of cardiovascular diseases in China are still on the rise. In particular, the rural areas have seen a continuous increase in cardiovascular disease mortality rates over recent years. The total inpatient costs for cardiovascular diseases are increasingly expensive, imposing a significant burden on public health. Therefore, there is an urgent need for cardiovascular disease prevention and control.

The National Health and Family Planning Commission, in its 2014 "Management Measures for Early Screening and Comprehensive Intervention for Cardiovascular Disease Populations," highlighted the importance of researching and evaluating suitable technologies for screening and comprehensive intervention for high-risk cardiovascular disease populations.The program, which was launched in multiple regions in 2022, has already enabled early cardiovascular disease screening for millions of individuals. Hence, it is expected that the Chinese government will continue to strongly support the development of convenient and rapid solutions for cardiovascular disease early screening.

2. Existing problem

Cardiovascular diseases are characterized by high recurrence rates, multiple complications, high incidence, and high disability and mortality rates. However, early diagnosis and timely treatment can significantly control cardiovascular diseases, reducing mortality rates. Early screening for cardiovascular diseases is crucial. Currently, many patients do not prioritize early screening for cardiovascular diseases. High-risk individuals and those with mild symptoms like dizziness and palpitations often fail to recognize the risk of cardiovascular diseases. They delay seeking medical attention, resulting in serious consequences.

3. Medical device registration2

Our product falls into the category of medical devices. After optimizing the product and expanding production capabilities, our team plans to employ the Tigentech Company to conduct clinical sample testing (CRO). Currently, we have established collaborations with tertiary hospitals in Liaoning Province, such as Dalian University Affiliated Central Hospital, Dalian Medical University Affiliated Second Hospital, and Liaoning Provincial Cancer Hospital. We anticipate completing testing for two thousand clinical cases within three to six months, with an expected investment of twenty million yuan. This rapid progress in clinical trials will enable us to apply for Class III medical device permits.

4. Target Users

Through research and competitor analysis, we have identified issues and gaps in current solutions, necessitating further segmentation of our target market to optimize our final product according to their specific needs. To achieve this, we have designed surveys and conducted in-depth interviews with target users, including post-cardiovascular disease patients and high-risk individuals, and have reached the following conclusions:

1.Post-cardiovascular disease patients typically do not receive post-discharge follow-up from hospitals and often rely on self-monitoring methods such as blood pressure measurements to assess their health. Among our interviewees, 30% experienced a recurrence of old conditions and had to be readmitted after being discharged. Patients are generally reluctant to visit hospitals for regular self-checks due to the complex and time-consuming nature of cardiovascular disease examinations in hospitals. This indicates a lack of effective post-discharge monitoring and management in the clinical practice of cardiovascular diseases in China, with the current convenience level of cardiovascular disease testing being insufficient. Patients are in urgent need of a method that allows them to quickly assess their health status and provides early warning in case of emergencies.

2.During the interview process, our samples included respondents from both urban and rural areas. We found that patients in rural areas often receive inadequate treatment, and the physical condition of high-risk individuals in rural areas is relatively worse compared to urban areas. This is primarily because healthcare standards in rural China are relatively lower, and most rural residents have a lower awareness of chronic disease prevention and treatment. They often do not have the habit of seeking timely medical attention, and fewer rural residents have the opportunity for comprehensive physical examinations or regular screenings.

Conversations with hospital doctors also provided us with valuable insights and recommendations. Doctors pointed out that due to the rapid onset and high fatality of cardiovascular diseases, a simpler external testing method, based on their diagnostic experience, would save a significant amount of healthcare resource costs for hospitals and reduce the threat of cardiovascular diseases to individuals.

Taking all of this into account, we understand that our sales channels should not be limited to hospital partnerships alone. We should also directly target consumers, particularly focusing on areas with relatively weak healthcare resources, such as rural areas. Based on their needs, we will further enhance our product. We have ultimately identified three categories of target users:

Category 1 Target User Group: Hospitals and Retail Pharmacies

In the early stages to build recognition and expand sales channels, our company is committed to establishing partnerships with hospitals and retail pharmacies in Dalian and its surrounding areas. We will collaborate with these institutions to achieve cooperative sales, using a profit-sharing model for mutual benefit. By leveraging the platforms of hospitals and pharmacies, we aim to gradually cultivate recognition among consumers and expand our market further.

Category 2 Target User Group: Smart Communities

Smart communities are increasingly taking measures to assess residents' quality of life and health status. Therefore, many communities install convenient medical examination equipment for residents. Our company is dedicated to providing integrated testing kits and equipment for these communities, facilitating community health projects. This approach will ensure early screening and detection of cardiovascular diseases for community residents. Additionally, we will offer regular free clinics and in-depth data analysis services to the communities using our equipment, providing further recommendations and analysis for high-risk individuals identified by our devices, thus reducing the risk of diseases.

Category 3 Target User Group: Urban and Rural Residents

In rural areas of China, medical facilities are relatively underdeveloped compared to urban areas. Many rural residents face challenges in receiving timely screening and treatment for cardiovascular diseases, leading to delayed optimal treatment. Therefore, we aim to benefit rural patients by offering more straightforward and convenient services. Initially, we will conduct free clinics in rural areas, offering further diagnosis and treatment recommendations to patients at risk of cardiovascular diseases. We will recommend sales to high-risk and diagnosed patients, providing precise diagnosis and treatment plans for rural residents to address their challenges in seeking medical attention.

5. User Manual

Our users generally lack medical expertise, so we need to simplify the usage of our testing kits to enable more patients to quickly understand the testing methods. We also need to ensure that the testing results are clear and reasonable, allowing patients to understand their health status and disease risk promptly.

6. Market Risks

6.1. Insufficient Attractiveness to Users

Solution: Understand market demands from the team structure and development process perspective.

1. Market promotion focuses on "promoting early screening for cardiovascular diseases," and R&D is guided by "easy realization of early screening services and reduced risk through regular screening."

2. Establish a user-oriented team culture, with all employees participating in user communication to collect feedback, continually improve development, enhance products, and monitor customer evaluations.

3. Segment user groups and conduct in-depth research on different target groups when developing services. Fine-tune product development based on the specific needs of each group.

6.2. Entry of Competitive Products Threatening Our Product's Advantages

Solution: Concentrate on specialization to enhance product advantages.

1. Evaluate each feature for development based on dimensions such as "demand level, target group size, development complexity, relevance to core functions, and competitive product advantages." Concentrate limited resources on developing the highest-scoring features.

2. Focus enterprise efforts and resources on core products, striving for deep and ultimate core competitiveness.

3. Promote collaborative research and development with laboratories and research teams in relevant medical and academic institutions, applying technologies favorable for improving "early screening for cardiovascular diseases and data collection for software analysis" to the product.

4. Maintain team cohesion through both material and spiritual means to prevent the loss of key personnel.

5. Establish an independent "Enterprise Competitive Intelligence Analysis" department responsible for analyzing competitor movements, conducting market analysis, and providing long-term decision-making support to the leadership.

Target Layer System Layer Indicator Layer
Prioritize the Requirements Related to The Project Quality Detection accuracy; Shelf life of reagent kit and test paper; Storage conditions of reagent kit and test paper; Error control; Quality control between different batches; The science of the principle of the project; Specificity of test objects; Detection sensitivity; Accuracy of detection method
Safety Waste disposal during production; Waste disposal during use; Sample handling; Safety in use
Ethics Sampling methods; Feedback format for test results; Protection of privacy data
Respect Personalized needs of cardiovascular disease patients
Public Health Sample contamination; Risk of cross-infection
Innovation Technical innovation; Business model innovation; Product or service innovation; Marketing innovation; Organizational management
Efficiency Production cycle; Detection time; Level of detail in the instructions; Ease of use; variability in data interpretation and understanding among different users
Costs Environmental impact; Stability; Reagent production and packaging; User storage conditions; Transportation conditions; Medical waste disposal